Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)Depreciation ExpenseEBIATGross ProfitLeasesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Amicus Therapeutics (FOLD) Shares Issued (2016 - 2025)

Amicus Therapeutics filings provide 15 years of Shares Issued readings, the most recent being -$145000.0 for Q3 2025.

  • On a quarterly basis, Shares Issued fell 108.03% to -$145000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was -$6.1 million, a 137.31% decrease, with the full-year FY2023 number at $10.3 million, up 139.53% from a year prior.
  • Shares Issued hit -$145000.0 in Q3 2025 for Amicus Therapeutics, down from $40000.0 in the prior quarter.
  • In the past five years, Shares Issued ranged from a high of $11.8 million in Q1 2021 to a low of -$6.1 million in Q4 2024.
  • Median Shares Issued over the past 5 years was $863000.0 (2024), compared with a mean of $1.6 million.
  • Biggest five-year swings in Shares Issued: plummeted 2963.33% in 2022 and later surged 827.68% in 2023.
  • Amicus Therapeutics' Shares Issued stood at $30000.0 in 2021, then soared by 3596.67% to $1.1 million in 2022, then surged by 827.68% to $10.3 million in 2023, then plummeted by 159.51% to -$6.1 million in 2024, then soared by 97.63% to -$145000.0 in 2025.
  • The last three reported values for Shares Issued were -$145000.0 (Q3 2025), $40000.0 (Q2 2025), and $105000.0 (Q1 2025) per Business Quant data.